NVS - Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants Toddlers | Benzinga
Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.
The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA (nusinersen) over two years in infants and toddlers with spinal muscular atrophy (SMA) who have unmet clinical needs after treatment with Novartis AG’s (NYSE:NVS) Zolgensma (onasemnogene abeparvovec).
Spinal muscular atrophy (SMA) is a disorder affecting the motor neurons-nerve cells that control voluntary muscle movement. These cells are located in the spinal cord.
Also Read: Biogen Could ...